fda announcement tirzepatide approves (Zepbound) injection for chronic weight management, with 72-week trials showing statistically significant body-weight reduction in adults with obesity or overweight FDA Approves Tirzepatide, A Potential

(Gut Hormones) (Gut Hormones) , , ,

As generic GLP1s flood the field, expect pricing pressure, new entrants like Hims &Hers and Apotex, and even strain on domestic supply as U.S

Heres a practical, evidence-based roadmap for women over 50 navigating eligibility, safety, insurance, and next steps.

Learn about Semaglutide: indications, safety, eligibility, and how our telemedicine team evaluates your case

A once-weekly injectable glucose-dependent insulinotropic polypeptide/GLP-1 dual agonist conferred up to 14.7% weight loss at 13 weeks for adults with overweight or obesity, according to findings from the VENTURE trial published in Obesity